TLDR mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    PP405 is a novel small molecule developed by Pelage Pharmaceuticals for the treatment of hair loss, specifically targeting mitochondrial pyruvate carrier (MPC). PP405 aims to activate hair follicle stem cells and restore the natural hair growth cycle.

    Pelage Pharmaceuticals' research is based on stem cell signaling pathways and the regulation of hair follicle cycles. PP405 is designed to inhibit MPC, a protein involved in various physiological processes. By blocking MPC, PP405 activates the hair growth cycle, transitioning dormant hair follicles to the growth phase and promoting the formation of normal hair follicles.

    Mouse studies conducted at UCLA demonstrated the efficacy of PP405 in accelerating the hair cycle and generating normal hair follicles within a relatively short timeframe of 30 to 40 days. These results were published in Nature Cell Biology in 2017.

    Pelage Pharmaceuticals conducted a Phase 1 clinical trial to assess the safety and tolerability of PP405. The trial, which enrolled 20 male participants, showed that PP405 was well tolerated with no reported adverse effects. Results also indicated successful engagement of the target molecule and proof of mechanism. They claim that PP405 was designed with "properties that get the molecule to stay in the scalp and not enter the bloodstream", and that the initial trial backs up this assertion.

    Building on the Phase 1 results, Pelage Pharmaceuticals is entering a Phase 2 clinical trial that will enroll both men and women to evaluate PP405's efficacy in various types of alopecia. The company aims to develop a universal treatment suitable for everyone.

    Further clinical development and evaluation in Phase 2 trials will elucidate PP405's potential as an effective and safe therapeutic option for individuals experiencing hair loss.


    20 / 20 results

    Community Join

    8 / 8 results